ROIVANT SCIENCES LTD. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ROIVANT SCIENCES LTD. payments for repurchase of common stock for the quarter ending 2026-06-30 was $206.73M, a 0.75% decline year-over-year.
- ROIVANT SCIENCES LTD. payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. payments for repurchase of common stock for the quarter ending 2025-06-30 was $208.29M, a 67.88% decline year-over-year.
- ROIVANT SCIENCES LTD. payments for repurchase of common stock for fiscal 2025 was $1.29B.
- ROIVANT SCIENCES LTD. payments for repurchase of common stock for fiscal 2024 was $0.00.
- ROIVANT SCIENCES LTD. payments for repurchase of common stock for fiscal 2023 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $206.73M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $503.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $747.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $208.29M 10-Q · filed 2026-08-06 | $853.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $295.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $1.29B 10-K · filed 2025-05-29 |
| 2024-12-31 | $243.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $997.79M derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-09-30 | $106.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $754.44M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $648.38M 10-Q · filed 2025-08-11 | $648.38M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $0.00 10-K · filed 2025-05-29 |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | |
| 2023-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $0.00 10-K · filed 2025-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |